Unlock instant, AI-driven research and patent intelligence for your innovation.

Related impurities of olmesartan medoxomil and preparation method thereof

A technology for olmesartan medoxomil and impurities, which is applied to the new olmesartan medoxomil-related impurities and the field of preparation thereof, can solve problems such as the need for further research on the synthesis method, and achieve the effect of improving quality control technology

Active Publication Date: 2020-11-06
CHENGDU BRILLIANT PHARMA CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In actual testing, it is often necessary to synthesize related impurities as reference substances. Although the synthesis methods of the above-mentioned impurities have been reported, olmesartan medoxomil contains other impurities, and their synthesis methods need to be further studied.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Related impurities of olmesartan medoxomil and preparation method thereof
  • Related impurities of olmesartan medoxomil and preparation method thereof
  • Related impurities of olmesartan medoxomil and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] The preparation of embodiment 1 olmesartan medoxomil degradation impurity AMST-Z8

[0058] Add 20g of olmesartan medoxomil, 2.01g of p-toluenesulfonic acid and 100ml of toluene into a 250ml three-necked flask at room temperature, raise the temperature to 95°C for 3.5h, and the system is two-phase. Let the reaction solution stand still, separate the oily substance in the lower layer, stir with 50ml 5% sodium hydroxide aqueous solution at room temperature for 30min, then use glacial acetic acid to adjust the pH of the system to 3~4, a brown solid precipitates, continue to stir for 20min, then filter, and filter the cake with 30ml×5 After washing with water once, it was blown-dried at 60° C. for 4 hours to obtain 11.5 g of brown solid AMST-Z8 with a yield of 75%.

Embodiment 2

[0059] Embodiment 2 Preparation of Olmesartan Medoxomil Degradation Impurity AMST-Z8

[0060] Dissolve 15g of olmesartan medoxomil in 90ml of 1,4-dioxane solution at room temperature, stir to dissolve, add 10ml of 6% hydrogen chloride in 1,4-dioxane solution into a 250ml three-necked flask, heat up to 90 ℃ reaction 3h, the system is two-phase. Let the reaction solution stand still, separate the oily substance in the lower layer, stir with 40ml of 5% sodium hydroxide aqueous solution at room temperature for 30min, then adjust the pH of the system to 3-4 with glacial acetic acid, a brown solid precipitates, continue to stir for 20min, then filter, and filter the cake with 30ml×5 times After washing with water, it was air-dried at 60° C. for 4 hours to obtain 7.7 g of brown solid AMST-Z8 with a yield of 67%.

[0061] AMST-Z8 structure confirmation:

[0062] 1 H NMR (400MHz, d 6 -DMSO): δ7.63-7.59(m, 2H), 7.54-7.47(m, 2H), 7.07(d, J=8.0Hz, 2H), 6.93(d, J=8.0Hz, 2H), 5.50( s...

Embodiment 3

[0063] The preparation of embodiment 3 olmesartan medoxomil impurity AMST-Z5 and AMST-Z7

[0064] (1) 11.1 g of AMST-SM2, 4.5 g of AMST-SM1-Z1 and 0.6 g of LiOH were sequentially added to 60 ml of DMA at room temperature, kept at 65 °C and stirred for 2 h. Slowly add the reaction solution dropwise to 500ml of water with stirring, and a solid precipitates, and is filtered, and the filter cake is washed with 100ml×3 times of water. The obtained solid was separated and purified by chromatographic column to obtain impurities 3.2g AMST1-Z6 (yield 22.85%), 9.5g AMST1-Z7 (yield 67.8%), total yield: 90.65%.

[0065] (2) Dissolve 3.0g AMST1-Z6 in 20ml of acetonitrile at room temperature, then add 0.16g of purified water, 4.2g of cesium carbonate, stir at room temperature for 5 hours, then add 4-chloromethyl-5-methyl-1,3- Dioxol-2-one 1.2g, add and stir at room temperature for 6h, the reaction system is extracted with EA and water, the organic phase is washed with saturated aqueous sod...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses olmesartan medoxomil related impurities and a preparation method thereof, discloses three novel related impurities AMST-Z8, AMST-Z5 and AMST-Z7 in olmesartan medoxomil and provides a synthetic method of the three related impurities. The related impurities can be used as reference substances in follow-up quality detection or used for other research, and a quality control technology for olmesartan medoxomil can be further improved.

Description

technical field [0001] The invention relates to the field of olmesartan medoxomil-related impurities, in particular to new olmesartan medoxomil-related impurities and a preparation method thereof. Background technique [0002] Olmesartan medoxomil (olmesartan medoxomil), the chemical name is 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl) Benzene-4-yl]methyl]-1H-imidazole-5-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, produced by Japan The angiotensin Ⅱ receptor antagonist developed by Sankyo Company was approved by the FDA in April 2002. It is clinically used to treat hypertension. It is an ideal antihypertensive drug and has good curative effect on various types of hypertension. Its outstanding feature is its long half-life, which can effectively control blood pressure within a day, so it is more convenient to take. At the same time compared with other angiotensin II receptor antagonist drugs. It has the obvious advantages of small dose, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D403/10C07D405/14
CPCC07D403/10C07D405/14
Inventor 黄浩喜卓国清商国宁苏忠海
Owner CHENGDU BRILLIANT PHARMA CO LTD